Charbel Moussa, MD, PhD

Georgetown University

I am an Associate Professor of Neurology at Georgetown University Medical Center (GUMC). My expertise is in geriatric neurology with a special focus on movement and memory disorders. I received a Bachelor of Medicine, Bachelor of Surgery (MBBS), and Doctor of Philosophy (Ph.D) in Biomedical Sciences from the University of Sydney Australia. I am the director of GUMC Translational Neurotherapeutics Program and the Laboratory for Dementia and Parkinsonism ( I serve as the Principal Investigator of the GUMC Lewy Body Disease Association (LBDA) Research Center of Excellence. I am a neuroscientist focused on the role of tyrosine kinases and de-ubiquitinases on protein ubiquitination and proteasome-autophagy clearance in neurodegenerative diseases. In collaboration with the Medicinal Chemistry Core Center at Georgetown University I generated several tyrosine kinase inhibitors (TKIs) that are being investigated as potential therapies for neurodegenerative diseases. I have discovered the potential use of cancer drugs nilotinib (Abl/DDR inhibitor) and bosutinib (Src/Abl Inhibitor) as a treatment for neurodegenerative diseases. I identified a potential novel drug target known as discoidin domain receptor (DDR)-1 that can induce autophagic clearance of misfolded proteins in preclinical and clinical settings. I am a clinical trialist and a translational neuroscience investigator and I have designed and completed a number of Phase I-III clinical trials in Alzheimer’s, Parkinson’s, Dementia with Lewy Bodies (LBD) and Huntington’s disease. In collaboration with the Genomics and Epigenetics Shared Resources (GESR) at Georgetown University, I have been performing next generation whole genome miRNA sequencing in the cerebrospinal spinal fluid (CSF) of Parkinson’s, Alzheimer’s, Dementia with Lewy Bodies and Huntington’s patients to generate a comprehensive database of miRNAs that control autophagy, ubiquitination and inflammation genes with and without TKI treatment. I have wide expertise in the pre-clinical and clinical role of various TKIs and their promising effects on neurodegenerative pathologies. I have published widely in peer reviewed scientific and medical journals on the mechanisms, diagnosis, and treatment of neurodegenerative diseases. I am the Chief Scientific Officer of a start-up life sciences company (KeifeRX LLC) that aims to develop these TKIs through early and late-stage clinical studies in several neurodegenerative diseases (